Chapter 17: Hematopoietic Drugs

Hematopoietic Drugs begins by defining hematopoiesis as the continuous replacement of blood cells, a process that requires specific minerals, vitamins, and regulatory growth factors. Anemia is presented as a primary clinical concern, arising from nutritional deficits, chronic inflammation, or drug-induced marrow suppression. The discussion on minerals centers on iron metabolism, detailing how iron is absorbed in the intestines, transported via transferrin, and stored as ferritin for use in hemoglobin synthesis. The text contrasts oral iron salts, like ferrous sulfate, with parenteral options such as iron dextran, which are reserved for patients with severe depletion or oral intolerance. Emphasis is placed on the specific requirements for infants and pregnant women, as well as the diagnostic markers of microcytic hypochromic anemia. Moving to vitamins, the chapter highlights the indispensable roles of folic acid and vitamin B12 in DNA synthesis. It explains how deficiencies lead to megaloblastic anemia and warns of the critical necessity to distinguish between these deficiencies, as treating a B12 deficit with folate can mask hematologic symptoms while allowing irreversible neurological damage to progress. The role of intrinsic factor in B12 absorption and the management of pernicious anemia are also detailed. The summary further examines the revolution in treatment brought about by recombinant DNA technology, specifically the development of hematopoietic growth factors. Erythropoiesis-stimulating agents, such as epoetin and darbepoetin, are analyzed for their utility in treating anemia associated with chronic kidney disease and chemotherapy, alongside safety warnings regarding hemoglobin targets. The production of white blood cells is addressed through colony-stimulating factors like filgrastim and sargramostim, which are vital for recovering from chemotherapy-induced neutropenia and supporting bone marrow transplants. Furthermore, the chapter covers the management of low platelet counts using thrombopoietin receptor agonists and interleukins. Finally, the text introduces modern therapeutic strategies for sickle cell disease, describing how novel medications like voxelotor and crizanlizumab work to inhibit hemoglobin polymerization and reduce the frequency of painful vaso-occlusive crises. This comprehensive overview provides a deep understanding of the physiological and pharmacological interventions used to maintain blood cell homeostasis and treat diverse hematologic disorders.